IDiyas

For the Inventor, By the Inventor

Cambridge, MA, United States of America

James Neef

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 8.9

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Horsham, GB (2011)
  • Cambridge, MA (US) (2018)
  • Stow, MA (US) (2022 - 2024)

Company Filing History:

goldMedal11 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2011-2025

Loading Chart...
Loading Chart...
11 patents (USPTO):
1. 12365690 - Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Ca1.2 activators (2025-07-22),
2. 12122761 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2024-10-22),
3. 11919911 - Methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[b]pyridine-3-carboxylate and methyl (r)-2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate as CAV1.2 activators (2024-03-05),
4. 11820778 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2023-11-21),
5. 11548865 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2023-01-10),
6. 11485742 - 2-azaspiro[3.4]octane derivatives as M4 agonists (2022-11-01),
7. 11453679 - Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxylate compounds as Ca1.2 activators (2022-09-27),
8. 10112926 - Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-10-30),
9. 10004732 - Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-06-26),
10. 9862711 - Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-01-09),
11. 7994203 - Organic compounds (2011-08-09),

Title: Innovations and Contributions of Inventor James Neef

Introduction

James Neef is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 11 patents. His work focuses on developing innovative compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents are Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate, which serve as Ca1.2 activators. Additionally, he has developed 2-azaspiro[3.4]octane derivatives as M4 agonists, providing compounds that are pharmaceutically acceptable and have defined properties for therapeutic use.

Career Highlights

James Neef has built a successful career at Novartis AG, where he has been instrumental in advancing pharmaceutical research and development. His innovative approach and dedication to his work have led to numerous breakthroughs in drug development.

Collaborations

He has collaborated with notable colleagues, including Edward Charles Hall and Amy Calhoun, to further enhance the impact of his research and inventions.

Conclusion

James Neef's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a leading inventor. His work continues to influence the development of new therapeutic compounds that may benefit many.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…